SciELO - Scientific Electronic Library Online

vol.13 issue1Differences in metabolic syndrome diagnostic criteria are useful for identifying risk subjects, but loose relevance in patients with coronary diseaseEndovascular treatment in patients with iliocaval compression syndrome: experience in 17 cases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista Colombiana de Cardiología

Print version ISSN 0120-5633


VESGA, Boris E.  and  ECHEVERRI, Darío. Acetylsalicylic acid resistance in patients with chronic ischemic heart disease. Rev. Col. Cardiol. [online]. 2006, vol.13, n.1, pp.13-22. ISSN 0120-5633.

Introduction: platelet anti-aggregation is the "corner stone" in the treatment of cardiovascular disease. Acetylsalicylic acid is the therapy of choice in the prevention and treatment of coronary disease, in doses of 81 - 325 mg. Objective: to assess platelet aggregation in subjects with stable coronary disease receiving acetylsalicylic acid, in order to determine its prevalence resistance. Methods: cross-sectional descriptive study in 71 subjects of 40 or more years of age with diagnosis of stable angina, who were admitted for coronary angiography performance. A peripheral venous blood sample was obtained in order to determine the platelet aggregation through arachidonic acid, epinephrine, collagen and ADP in a HELENA PACKS-4 aggregometer. Resistance to the acetylsalicylic acid was defined when having aggregations greater than 20% with arachidonic acid. The statistical analysis was developed with the exact Fisher t test of Student and Mann-Whitney according to variable distribution. Results: 71 subjects were included; 51 were male (71.8%); mean age 63.5 ± 9.4 years. Risk factors: 52 (73.2%) had dyslipidemia, 48 (67.6%) arterial hypertension, 15 (21.1%) diabetes mellitus and 9 (12.7%) were cigarette smokers; in 31 (15.9%) arteriography showed one-vessel coronary disease, and multi-vessel disease in 58 (81.7%). The platelet aggregometric values obtained were: ADP: 64 ± 19.1%, collagen 72 ± 18.9%, epinephrine 43.8± 23.9% and arachidonic acid 26.1 ± 33.7%, being this one the best marker in the acetylsalicylic acid's effect. The prevalence of aspirin resistance was 28.2% (IC 95%: 18.1 -40.1). Conclusion: in our population, acetylsalicylic acid resistance is highly prevalent; for this reason, routine measurement of platelet aggregation in high risk patients must be considered, as well as the addition of another anti-aggregation drug (dual therapy) that may guarantee a better anti-thrombotic protection in patients with coronary disease.

Keywords : acetylsalicylic acid; platelet aggregation; coronary heart disease.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License